Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451151 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
A Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness, sponsored by Aderans Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT01451151: Completed Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness, sponsored by Aderans Research Institute.
NCT01451151 is a Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness that has completed, run by Aderans Research Institute. The registered enrollment target is 33 participants, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01451151, a Phase 2 study of Androgenetic Alopecia and Male Pattern Baldness, has completed, sponsored by Aderans Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
Conditions Studied
Interventions
- BIOLOGICAL Autologous cultured dermal and epidermal cells
Study Locations (2)
California
- Axis Clinical Trials, Inc. - Los Angeles
New York
- Axis Clinical Trials, Inc. - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-12 |
| Phase | Phase 2 |
What the finished NCT01451151 record still lists
NCT01451151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 163-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Autologous cultured dermal and epidermal cells is the first listed.
NCT01451151 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT01451151 about?
NCT01451151 is a clinical study titled "A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)". The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
What is the current status of trial NCT01451151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2010-12.
What conditions does trial NCT01451151 study?
This clinical trial studies the following conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness.
What interventions are being tested in trial NCT01451151?
The interventions under investigation include: Autologous cultured dermal and epidermal cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01451151?
This trial is sponsored by Aderans Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01451151 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01451151's enrollment target sits among peer trials
33 12th of 16 higher than 5 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia